India Globalization Capital, Inc. (NYSE MKT: IGC), a developer of cannabis-based therapies to treat a variety of life-altering conditions, this morning announced the publication of “Marijuana Could Help Treat Alzheimer’s: Here’s How It Would Work” on August 1, 2017, by Javier Hasse on the website of “HIGH TIMES,” a publication that’s served as the preeminent source for cannabis information since 1974. In the article, both Ram Mukunda, CEO of IGC, and Dr. Chuanhai Cao, the company’s key advisor, were quoted with respect to the potential therapeutic effects of THC on Alzheimer’s disease, which is noted as America’s most expensive ailment. “In Alzheimer’s Disease, beta-amyloid aggregates into a plaque-like substance that builds around the neurons and disrupts communication between them,” Mukunda stated in the publication. “So of course, if low-doses of THC can break up those plaques and prevent them from forming in the first place, it’s a huge breakthrough.” The full article is available for review at http://nnw.fm/5rWYd.
To view the full press release, visit http://nnw.fm/6bTyZ
About IGC
India Globalization Capital is engaged in the development of cannabis-based therapies to treat pain, PTSD, seizures, cachexia, chronic and terminal neurological and oncological diagnoses, and other life altering conditions. In support of this mission, IGC has assembled a portfolio of patent filings for its phytocannabinoid-based treatments. The company is based in Bethesda, Maryland. For more information visit www.igcinc.us
More from CBDNewsBreaks
Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) Spotlighted by Technical420
About CBDWire
CBDWire (CBDW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CBDNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CBDW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CBDW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CBDW brings its clients unparalleled visibility, recognition and brand awareness. CBDW is where news, content and information converge.
For more information please visit https://www.cbdwire.com
Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer
CBDWire (CBDW)
Denver, CO
cbdwire.com
303.498.7722 Office
[email protected]
